Keyphrases
Immune-related Adverse Events
100%
Immune Checkpoint Inhibitors
100%
Programmed Death-ligand 1 (PD-L1)
57%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
28%
Myocarditis
28%
Tim-3
28%
TIGIT
28%
Lymphocyte Activation gene-3 (LAG-3)
28%
Monoclonal Antibody
14%
Cancer Cells
14%
Lung
14%
Liver
14%
Cancer Treatment
14%
T Cells
14%
In Cancer
14%
Clinical Data
14%
Immunoglobulin
14%
Cancer Therapy
14%
Ongoing Clinical Trials
14%
Cardiovascular System
14%
Patient Outcomes
14%
Cancer Patients
14%
Intestine
14%
Receptor Targets
14%
Preclinical Data
14%
Arrhythmia
14%
Cardiomyopathy
14%
Anti-tumor Response
14%
Inhibitory Receptors
14%
Potential Side Effects
14%
T Cell Immunoglobulin mucin-3
14%
Pericarditis
14%
Immune Checkpoint
14%
Cardiac Complications
14%
T Cell Suppression
14%
Immunoreceptor
14%
Medicine and Dentistry
Cardiovascular System
100%
Immune-Related Adverse Events
100%
Immune Checkpoint Inhibitor
100%
Atherosclerosis
28%
T Cell
28%
Cancer Therapy
28%
Myocarditis
28%
CTLA-4
28%
Programmed Death-Ligand 1
28%
Hope
14%
Neoplasm
14%
Receptor
14%
Malignant Neoplasm
14%
Cancer Cell
14%
Monoclonal Antibody
14%
Immunoglobulin
14%
Clinical Trial
14%
Cardiovascular System
14%
Side Effect
14%
Intestine
14%
Cardiomyopathy
14%
Pericarditis
14%
Cardiac Dysrhythmia
14%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Immune Checkpoint Inhibitor
100%
Malignant Neoplasm
57%
Atherosclerosis
28%
Myocarditis
28%
Cytotoxic T Lymphocyte Antigen 4
28%
Side Effect
14%
Clinical Trial
14%
Neoplasm
14%
Receptor
14%
Monoclonal Antibody
14%
Immunoglobulin
14%
Heart Arrhythmia
14%
Cardiomyopathy
14%
Hepatitis A Virus Cellular Receptor 2
14%
Pericarditis
14%